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Identity 
Other names: B3Gn-T6; beta3GNT6; BGnT-6; Beta-
1,3-N-acetylglucosaminyltransferase-6; Beta3Gn-T6; 
C3S; Core 3 synthase; MGC119334; MGC119336; 
MGC119337 
HGNC (Hugo): B3GNT6 
Location: 11q13.5 
Local order: -NA- 
Note 
B3GNT6 is a single-pass type II membrane protein 
belonging to the glycosyltransferase 31 family. 
DNA/RNA 
Note 
Human B3GNT6 is located on chromosome 11 in the 
region of q13.4. 
 
The schematic representation of human B3GNT6 gene and its 
transcript (ATG, translation start codon; TGA, translation stop 
codon; UTR, Untranslated region; ORF, Open reading frame). 
Description 
Human B3GNT6 gene is 7,111 bp in length, composed 
of 2 exons and 1 intron, and located at chromosome 
11q13.4. 
Transcription 
B3GNT6 transcript contains two exons. Exon 1 is 121
bp and exon 2 is 1,917 bp. The exon 2 contains 1,155 






acetylglucosaminyltransferase 6 (core 3 synthase) has 
384 amino acids and 43 KDa molecular weight. 
 
The predicted B3GNT6 structure contains a short N-terminal 
cytoplasmic tail (CT) (12 aa), a transmembrane domain (TM) 
(19 aa), a long stem region and catalytic domain (353 aa) at the 
C-terminal region. 
Description 
B3GNT6/C3S is single-pass type II membrane protein 
belonging to the glycosyltransferase 31 family. 
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Expression 
B3GNT6/C3S gene expression is restricted to mucus-
secretory tissues. The level of beta3GnT6 transcript 
expressed in various human tissues as measured by the 
real time PCR revealed that the expression level was
highest in the stomach, followed by the colon and small 
intestine. Skeletal muscle and testis expressed the 
beta3GnT6 transcript at a moderate level. The 
expression levels in the remaining tissues were very 
low or not detectable. Its expression was markedly 
down-regulated in gastric and colorectal carcinomas, 
which include both tumor tissues and cell lines-derived 




B3GNT6/C3S enzyme catalyzes the transfer of 
GlcNAc from UDP-GlcNAc to GalNAcalpha1-Ser/Thr 
(Tn antigen) to form the core 3 structure 
(GlcNAcbeta1-3GalNAcalpha1-Ser/Thr). Core 3 can 
be extended by the addition of galactose and then other 
sugars to generate biologically important epitopes or 
serves as the precursor for the formation of core 4, 
which in turn can be further elaborated to form more 
complex structure. Core 3-containing O-glycans are 
found in the secreted mucins produced in the mucus-
secretory tissues. Loss of core 3 synthase results in the 
loss of not only core 3 glycans but also core 4 glycans. 
Loss of core 3 could lead to the production of secreted 
mucins with compromised mucus protection function. 
As a result, mucus would be more dehydrated, bacteri  
would be inefficiently cleared from the system, and 
chronic inflammation would be developed, which 
eventually would result in development of cancer. A 
mouse model devoid of core 3 synthase gene has been 
shown to develop colon cancer. Because the loss of this 
gene leads to development of colon cancer, 
B3GNT6/C3S gene is a tumor suppressor gene. 
Homology 
An alignment of the amino acid sequences of five 
B3GnTs made using ClustalW showed 41, 54, 42, and 
35% sequence identity between B3GnT6 and B3GnT2, 
B3GnT3, B3GnT4, and B3GnT5, respectively, and this 
sequence similarity was limited to the putative catalytic 
domains. Five cysteine residues were conserved among 
these five B3GnTs. However, only B3GNT6/C3S 
exhibits significant core 3 synthase activity. 
Implicated in 
Gastric and Colorectal carcinomas 
Note 
Colorectal cancer, which is also called colon cancer  
or large bowel cancer, includes cancerous growths in  
the colon, rectum and appendix. Loss of function of the  
mucus layer is one major cause of this cancer. 
Globally, cancer of the colon and rectum is the third 
leading cause of cancer in males and the fourth leading 
cause of cancer in females. The frequency of colorectal 
cancer varies around the world. It is common in the 
Western world and is rare in Asia and Africa. In 
countries where the people have adopted western diets, 
the incidence of colorectal cancer is increasing. 
Colorectal cancer can take many years to develop and 
early detection of colorectal cancer greatly improves 
the chances of a cure. Therefore, screening for the 
disease is recommended in individuals who are at 
increased risks. Prevention and early detection are key 
factors in controlling and curing colorectal cancer. 
Indeed, colorectal cancer is the second most 
preventable cancer, after lung cancer. 
Prognosis 
B3GNT6/C3S is down-regulated in gastric and 
colorectal carcinomas, suggesting that it may be used 
as a marker for distinguishing between benign 
adenomas and premalignant lesions. 
Oncogenesis 
O-linked oligosaccharides (O-glycans) are the primay 
components of the intestinal mucus layer that covers 
the gastrointestinal epithelium. This layer is a dense, 
carbohydrate-rich matrix that consists primarily of
mucins containing multiple serine and threonine 
residues, which have been modified by O-glycans and 
account for 80-90% of the mucin mass. The mucus 
layer and epithelial cells comprise an intestinal brrier 
that protects epithelial and intestinal mucosal immune 
cells from potentially harmful luminal microflora and 
food components. Among all mucin glycan core 
structures, Core 3 and core 4 are unique to secreted 
mucins, which may play important roles in protecting 
the molecular integrity of these mucins and enable 
them to perform their functions under extreme harsh 
conditions, such as gastric and colonic environment. 
Loss of these functions resulted from the loss of core 3 
synthase is thought to initiate oncogenesis in the 
gastrointestinal tract. 
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